ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 082

Anti-Mitochondrial Autoantibodies Are Associated with Dysphagia in Juvenile and Adult Myositis, and with Persistent Weakness and Cardiomyopathy in Adult Myositis

Sara Sabbagh1, Iago Pinal-Fernandez 2, Maria Casal-Dominguez 3, Frederick W. Miller 4, Lisa G. Rider 5, Andrew Mammen 3 and Lisa Christopher-Stine 6, 1NIH/NIAMS, Bethesda, 2National Institutes of Health, Bethesda, 3NIH, Bethesda, 4Bethesda, 5NIEHS, NIH, Garrett Park, 6Johns Hopkins University, Baltimore

Meeting: 2020 Pediatric Rheumatology Symposium

Keywords: anti-mitochondria antibody, juvenile dermatomyositis, Myositis

  • Tweet
  • Email
  • Print
Session Information

The 2020 Pediatric Rheumatology Symposium, originally scheduled for April 29 – May 2, was postponed due to COVID-19; therefore, abstracts were not presented as scheduled.

Date: Friday, May 1, 2020

Title: Poster Session 2

Session Type: ACR Abstract Session

Session Time: 5:00PM-6:00PM

Background/Purpose: We analyzed the prevalence of anti-mitochondrial autoantibodies (AMA) in both juvenile-(JM) and adult-onset myositis cohorts and investigated phenotype differences between juvenile and adult myositis patients with or without AMA.

Methods: We screened sera from myositis patients who were classified as dermatomyositis (DM), polymyositis (PM), or inclusion body myositis (IBM) based on Bohan and Peter or Grigg criteria, including 342 juvenile-onset (JM) and 619 adult-onset patients (216 DM, 222 PM, 140 IBM, and 19 amyopathic DM (ADM)), and from healthy controls, including 92 children and 164 adults, for AMA by ELISA. Clinical characteristics were compared between myositis patients with and without AMA.

Results: AMA were present in 1% (4/342) of JM patients, 5% (32/619) of adult myositis patients (16 DM, 10 PM, 4 IBM, and 1 ADM), and 1% of both juvenile and adult healthy controls. Of the 4 JM patients with AMA, 3 had DM and 1 had PM. Three of the four AMA+ JM patients had dysphagia and all 4 patients had a moderate to severe disease onset. There were no other clinical features or medication usage associated with AMA in JM patients. In the 619 adult myositis patients, AMA were associated with cardiomyopathy (16% vs 5%, p=0.01). Additional clinical data available in 480 of the 619 patients followed longitudinally showed that AMA were associated with persistent muscle weakness over an average of 6 visits (90% vs 62%, p=0.005), Raynaud’s phenomenon (43% vs 14%, p< 0.001), and dysphagia (63% vs 36%, p=0.003). Adult patients with AMA also more frequently received glucocorticoids (90% vs 67%, p=0.04) and intravenous immunoglobulin (60% vs 29%, p=0.003).

Conclusion: AMA are present in 1% of JM and 5% of adult myositis patients. In juvenile myositis AMA are not disease specific; however, patients often had dysphagia similar to adult-onset myositis patients with AMA. In adult-onset myositis patients, AMA are also associated with chronic muscle weakness, cardiomyopathy and Raynaud’s. Our data suggest that AMA may have a role in disease management in myositis, and their presence necessitates cardiomyopathy screening in adult-onset, but not juvenile-onset myositis patients.


Disclosure: S. Sabbagh, None; I. Pinal-Fernandez, None; M. Casal-Dominguez, None; F. Miller, None; L. Rider, None; A. Mammen, None; L. Christopher-Stine, None.

To cite this abstract in AMA style:

Sabbagh S, Pinal-Fernandez I, Casal-Dominguez M, Miller F, Rider L, Mammen A, Christopher-Stine L. Anti-Mitochondrial Autoantibodies Are Associated with Dysphagia in Juvenile and Adult Myositis, and with Persistent Weakness and Cardiomyopathy in Adult Myositis [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 4). https://acrabstracts.org/abstract/anti-mitochondrial-autoantibodies-are-associated-with-dysphagia-in-juvenile-and-adult-myositis-and-with-persistent-weakness-and-cardiomyopathy-in-adult-myositis/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2020 Pediatric Rheumatology Symposium

ACR Meeting Abstracts - https://acrabstracts.org/abstract/anti-mitochondrial-autoantibodies-are-associated-with-dysphagia-in-juvenile-and-adult-myositis-and-with-persistent-weakness-and-cardiomyopathy-in-adult-myositis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology